A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the effectiveness and tolerability of MK8141 in lowering blood pressure in patients who have hypertension (high blood pressure).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)

NCT01104545

Hypertension

COMPLETED PHASE1

A Multiple Dose Study of MK-3614 (MK-3614-002)

NCT01033643

Hypertension

COMPLETED PHASE1

A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009)

NCT01370655

Hypertension

COMPLETED PHASE1

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

NCT04936035

Hypertension

COMPLETED PHASE2

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)

NCT00886600

Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Arm 1: Drug 250 mg

Group Type EXPERIMENTAL

MK8141

Intervention Type DRUG

MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period

2

Arm 2: Drug 500 mg

Group Type EXPERIMENTAL

MK8141

Intervention Type DRUG

MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period

3

Arm 3: Active Comparator

Group Type ACTIVE_COMPARATOR

Enalapril

Intervention Type DRUG

Enalapril 20 mg tablet once daily. 4 week treatment period.

4

Arm 4: Pbo Comparator

Group Type PLACEBO_COMPARATOR

Comparator: placebo (unspecified)

Intervention Type DRUG

MK8141 Pbo tablet once daily. 4 week treatment period.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK8141

MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period

Intervention Type DRUG

Comparator: placebo (unspecified)

MK8141 Pbo tablet once daily. 4 week treatment period.

Intervention Type DRUG

Enalapril

Enalapril 20 mg tablet once daily. 4 week treatment period.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vasotec®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* You are 35 to 65 years of age
* In the past 14 days you have not been treated for hypertension
* In the past 14 days you have not taken more than 2 medications to treat high blood pressure
* You are a woman who is not able to have children or do not use birth control

Exclusion Criteria

* You are taking more than 2 medications to treat high blood pressure
* You have a history of a stroke, transient ischemic attack (TIA), heart attack, congestive heart failure, coronary artery bypass surgery
* You have Type 1 or 2 diabetes mellitus
* You have an active liver disease, gallbladder disease, or bowel disease
* You are HIV positive
* You have certain types of cancer
* You abuse drug or alcohol
* You have participated in another clinical study in last 4 weeks

Minimum Eligible Age

35 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No